| Patients with intrahepatic cholangiocarcinoma and fibroblast growth factor receptor (FGFR)-2 alterations appear to have longer overall survival and longer progression-free survival on second-line systemic therapy compared with patients without FGFR alterations. |
| The apparent advantage in progression-free survival during second-line systemic therapy in patients with intrahepatic cholangiocarcinoma and FGFR2 alterations may have an implication to the value of first-line chemotherapy. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.